GSTT1 as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer
暂无分享,去创建一个
Yung-Hyun Choi | S. Moon | W. Kim | Y. Ha | S. Yun | Chunri Yan | P. Jeong | Yong-June Kim | Sang-Cheol Lee | Wun-Jae Kim | Min Su Lym | S. Moon
[1] Wun-Jae Kim,et al. Environmental factors promoting bladder cancer , 2009, Current opinion in urology.
[2] S. Chanock,et al. Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis , 2009, International journal of cancer.
[3] N. Malats,et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis , 2009, International journal of cancer.
[4] M. Babjuk,et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.
[5] T. Reckwitz,et al. The Influence of Polymorphisms of Glutathione S-Transferases M1 and M3 on the Development of Human Urothelial Cancer , 2008, Journal of toxicology and environmental health. Part A.
[6] P. Schellhammer,et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.
[7] Leah E. Mechanic,et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. , 2007, Journal of the National Cancer Institute.
[8] Wun-Jae Kim,et al. Biomarkers in Bladder Cancer: Present Status and Perspectives , 2007, Biomarker insights.
[9] D. Michaud,et al. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women , 2006, BMC Cancer.
[10] A. Zlotta. NAT2 Slow Acetylation, GSTM1 Null Genotype, and Risk of Bladder Cancer: Results from the Spanish Bladder Cancer Study and Meta-Analyses , 2006 .
[11] Wun-Jae Kim,et al. GSTT1-null genotype is a protective factor against bladder cancer. , 2002, Urology.
[12] A. Evangelou,et al. The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer. , 2002, Anticancer research.
[13] Henry J. Lin,et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. , 2002, American journal of epidemiology.
[14] F. Greene. The American Joint Committee on Cancer: updating the strategies in cancer staging. , 2002, Bulletin of the American College of Surgeons.
[15] N. Rothman,et al. Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. , 2002, Cancer letters.
[16] R. Houlston,et al. Glutathione S-transferase μ1 (GSTM1) status and bladder cancer risk : a meta-analysis , 2000 .
[17] Ho Kim,et al. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. , 2000, The Journal of urology.
[18] R. Strange,et al. Glutathione S-transferase: genetics and role in toxicology. , 2000, Toxicology letters.
[19] Y. H. Lee,et al. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. , 2000, The Journal of urology.
[20] T. Kawamoto,et al. Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. , 1998, Cancer letters.
[21] J. Brockmöller,et al. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. , 1996, Cancer research.
[22] C. Bloomfield,et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect , 1996, The Lancet.
[23] Jack A. Taylor,et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.
[24] A. Miller,et al. Tobacco use, occupation, coffee, various nutrients, and bladder cancer. , 1980, Journal of the National Cancer Institute.
[25] Li-Rong Zhang,et al. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. , 2009, Cancer detection and prevention.
[26] D. Michaud,et al. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women , 2006, BMC Cancer.
[27] Wun-Jae Kim,et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. , 2005, Urology.
[28] R. Houlston,et al. Glutathione S-transferase mu1 (GSTM1) status and bladder cancer risk: a meta-analysis. , 2000, Mutagenesis.
[29] E. Biros,et al. The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. , 1999, Physiological research.
[30] H. Ozen. Bladder cancer. , 1998, Current opinion in oncology.
[31] T. Reckwitz,et al. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder , 1996, Archives of Toxicology.